Advertisement

MoonLake Immunotherapeutics MLTX

Set alert

Price alert · MLTX

All alert types
11.78 USD -0.79 -6.28%

At close · Oct 30

11.78 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
11.78 × 2
Ask
11.79 × 2
11.71 Day range 12.63
9.55 52-week range 22.16
YTD
-10.62%
1 year
+20.08%
Open
12.44
Prev close
12.57
Mkt cap
1.00B
Vol
1.13M
Avg vol
1.69M
EPS
-3.83
P/E
0.00
Div yield
0.00%
More statistics
Low
11.71
High
12.63
Forward P/E
-3.54
Beta
1.08
Short ratio
4.01
Inst. own
87.73%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
12.60
200-d avg
16.49
1y target
28.54

2Y chart

Chart tools
Interval

Events in this range
  • Aug 5, 2025Earnings: -0.87; estimate -0.73; surprise -19.18%
  • Nov 5, 2025Earnings: -1.1; estimate -0.89; surprise -23.6%
  • Feb 25, 2026Earnings: -0.92; estimate -0.92; surprise 0%
  • May 11, 2026Earnings: -0.98; estimate -0.91; surprise -7.69%
  • Jun 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Jun 9, 2026Rating: BTIG · Buy → Buy
  • Jul 1, 2026Rating: Leerink Partners · Outperform → Outperform
  • Jul 20, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Aug 10, 2026Earnings: -0.84; estimate -0.90859; surprise 7.55%
  • Aug 13, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Oct 5, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (97)
NameDateAgo
MACD: Buy SignalOct 20, 20261 week ago
MACD: Sell SignalOct 16, 20262 weeks ago
RSI: OversoldOct 1, 20261 month ago
MACD: Buy SignalSep 30, 20261 month ago
MACD: Sell SignalSep 29, 20261 month ago
RSI: OversoldSep 28, 20261 month ago
MACD: Buy SignalSep 22, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
RSI: OversoldSep 9, 20261 month ago
MACD: Buy SignalSep 4, 20261 month ago
SMA: BearishAug 20, 20262 months ago
SMA: BullishAug 19, 20262 months ago
SMA: BearishAug 13, 20262 months ago
SMA: BearishJul 28, 20263 months ago
MACD: Sell SignalJul 14, 20263 months ago
MACD: Buy SignalJul 13, 20263 months ago
MACD: Sell SignalJul 1, 20264 months ago
RSI: OverboughtJun 22, 20264 months ago
SMA: BullishJun 17, 20264 months ago
MACD: Buy SignalJun 15, 20264 months ago
SMA: BullishJun 11, 20264 months ago
SMA: BearishJun 10, 20264 months ago
MACD: Sell SignalJun 8, 20264 months ago
SMA: BullishMay 21, 20265 months ago
MACD: Buy SignalMay 21, 20265 months ago
SMA: BearishMay 18, 20265 months ago
MACD: Sell SignalMay 18, 20265 months ago
SMA: BullishMay 11, 20265 months ago
SMA: BearishMay 7, 20265 months ago
SMA: BullishMay 6, 20265 months ago
MACD: Buy SignalMay 6, 20265 months ago
SMA: BearishMay 5, 20265 months ago
SMA: BullishMay 4, 20266 months ago
SMA: BearishApr 21, 20266 months ago
MACD: Sell SignalApr 21, 20266 months ago
MACD: Buy SignalApr 8, 20266 months ago
SMA: BullishApr 2, 20267 months ago
SMA: BearishApr 1, 20267 months ago
MACD: Sell SignalApr 1, 20267 months ago
MACD: Buy SignalMar 31, 20267 months ago
SMA: BullishMar 25, 20267 months ago
SMA: BearishMar 18, 20267 months ago
MACD: Sell SignalMar 3, 20268 months ago
MACD: Buy SignalFeb 17, 20268 months ago
MACD: Sell SignalJan 28, 20269 months ago
MACD: Buy SignalJan 9, 20269 months ago
RSI: OverboughtJan 9, 20269 months ago
SMA: BullishJan 8, 20269 months ago
SMA: BearishJan 2, 202610 months ago
MACD: Sell SignalDec 19, 202510 months ago
SMA: BullishDec 4, 202511 months ago
MACD: Buy SignalOct 16, 20251 year ago
SMA: BearishSep 29, 20251 year ago
SMA: BearishSep 29, 20251 year ago
MACD: Sell SignalSep 29, 20251 year ago
RSI: OversoldSep 29, 20251 year ago
MACD: Buy SignalSep 26, 20251 year ago
SMA: BullishSep 25, 20251 year ago
SMA: BearishSep 23, 20251 year ago
SMA: BullishSep 22, 20251 year ago
SMA: BearishSep 19, 20251 year ago
SMA: BullishSep 18, 20251 year ago
SMA: BearishSep 12, 20251 year ago
MACD: Sell SignalSep 10, 20251 year ago
RSI: OverboughtSep 8, 20251 year ago
MACD: Buy SignalSep 2, 20251 year ago
MACD: Sell SignalJul 29, 20251 year ago
RSI: OverboughtJul 23, 20251 year ago
RSI: OverboughtJul 17, 20251 year ago
MACD: Buy SignalJul 10, 20251 year ago
MACD: Sell SignalJul 8, 20251 year ago
MACD: Buy SignalJun 26, 20251 year ago
MACD: Sell SignalJun 16, 20251 year ago
RSI: OverboughtJun 3, 20251 year ago
MACD: Buy SignalJun 2, 20251 year ago
SMA: BullishMay 29, 20251 year ago
SMA: BearishMay 27, 20251 year ago
SMA: BullishMay 23, 20251 year ago
SMA: BearishMay 21, 20251 year ago
SMA: BullishMay 19, 20251 year ago
SMA: BearishMay 13, 20251 year ago
SMA: BullishMay 12, 20251 year ago
SMA: BearishMay 9, 20251 year ago
MACD: Sell SignalMay 9, 20251 year ago
SMA: BullishMay 8, 20251 year ago
SMA: BearishMay 7, 20251 year ago
SMA: BullishApr 21, 20251 year ago
MACD: Buy SignalApr 16, 20251 year ago
RSI: OversoldApr 8, 20251 year ago
MACD: Sell SignalApr 4, 20251 year ago
MACD: Buy SignalMar 17, 20251 year ago
RSI: OversoldMar 10, 20251 year ago
MACD: Sell SignalMar 3, 20251 year ago
MACD: Buy SignalFeb 28, 20251 year ago
MACD: Sell SignalFeb 14, 20251 year ago
MACD: Buy SignalJan 29, 20251 year ago
RSI: OversoldJan 16, 20251 year ago

Key statistics

Market cap
1.00B
Enterprise value
634.29M
Trailing P/E
0.00
Forward P/E
-3.54
PEG ratio
0.00
Price / sales
0.00
Price / book
2.30
EPS (TTM)
-3.83
Beta
1.08
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-131.86M
Total cash
537.03M
Total debt
101.53M
Return on equity
-67.47%
Shares outstanding
85.11M
Short % of float
12.69%
50-day average
12.60
200-day average
16.49

Analyst view

Consensus: buy

Buy
Price target (mean) 28.54 +142.3% upside
Target (low)
6.00
Target (mean)
28.54
Target (high)
50.00
Ratings (0m) 15 11 buy · 2 hold · 2 sell
  • Strong buy1
  • Buy10
  • Hold2
  • Sell2
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate -0.78081.

Earnings history

Financials — quick view

All financials
MLTX Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MLTX Net income — quarterly -61.80M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MLTX EPS — quarterly -0.84
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MLTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 2026-0.77———
Aug 10, 2026Jun 30, 2026-0.90859-0.84+0.07+7.55%
May 11, 2026Mar 31, 2026-0.91-0.98-0.07-7.69%
Feb 25, 2026Dec 31, 2025-0.92-0.920.000.00%
Nov 5, 2025Sep 30, 2025-0.89-1.10-0.21-23.60%
Aug 5, 2025Jun 30, 2025-0.73-0.87-0.14-19.18%

Upgrades / downgrades

MLTX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 5, 2026HC Wainwright & Co.reitBuyBuy
Aug 13, 2026HC Wainwright & Co.mainBuyBuy
Jul 20, 2026HC Wainwright & Co.reitBuyBuy
Jul 1, 2026Leerink PartnersmainOutperformOutperform
Jun 9, 2026BTIGreitBuyBuy
Jun 8, 2026HC Wainwright & Co.reitBuyBuy

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Sector
Healthcare
Industry
Biotechnology
Country
Switzerland

News

Your note

Sign in to keep a note on MLTX — it syncs with the Stock Master app.

Insider holders

MLTX insider holders
InsiderRelationLatest transactionDateShares held
BODENSTEDT MATTHIASChief Financial OfficerSaleJun 21, 20261,115,440
BVF PARTNERS L PBeneficial Owner of more than 10% of a Class of SecuritySaleMar 30, 20260
CHEN BIHUA X.FormerSaleSep 29, 20250
MOUKHEIBIR CATHERINEDirectorSaleJul 2, 20250
REICH KRISTIANOfficerSaleJul 26, 20260
SANTOS DA SILVA JORGEChief Executive OfficerSaleJul 9, 20262,774,890

Institution ownership

MLTX institution ownership
Holder% heldSharesValueReported
BVF Inc.18.80%16,001,284188.50MJun 29, 2026
Deep Track Capital, Lp8.22%6,999,02582.45MJun 29, 2026
T. Rowe Price Investment Management, Inc.5.03%4,280,62450.43MJun 29, 2026
Shaw D.E. & Co., Inc.3.95%3,365,50739.65MJun 29, 2026
Cormorant Asset Management, LP3.77%3,205,43337.76MJun 29, 2026
Jupiter Topco LLC3.63%3,085,90636.35MJun 29, 2026

Fund ownership

MLTX fund ownership
Holder% heldSharesValueReported
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App1.90%1,614,28919.02MJun 29, 2026
T. Rowe Price Small-Cap Value Fund, Inc.1.08%918,58610.82MJun 29, 2026
T. Rowe Price Health Sciences Fund, Inc.0.93%792,0729.33MJun 29, 2026
TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust0.71%605,4747.13MJun 29, 2026
JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund0.41%350,1344.12MJun 29, 2026
T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq0.20%167,7681.98MJun 29, 2026
Advertisement